Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From SomaLogic, Inc.
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
Scrip spoke with R&D head David Reese about improving R&D timelines and success rates, including through the use of genomics and proteomics, as data readouts near for key drugs in big indications.
GNS Healthcare wants to be on the forefront of the digital revolution in health care by offering its artificial intelligence powers to pharmaceutical and health-insurer customers to help them find the drivers of health outcomes and save costs along the way. It has also teamed up with research and patient foundations to expedite the R&D process, predict best treatment options for patients and create efficiencies for clinical trials.
- Research, Analytical Equipment & Supplies
- Diagnostic Equipment & Supplies
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools